keyword
MENU ▼
Read by QxMD icon Read
search

Armodafinil

keyword
https://www.readbyqxmd.com/read/28424564/new-developments-in-the-management-of-narcolepsy
#1
REVIEW
Vivien C Abad, Christian Guilleminault
Narcolepsy is a life-long, underrecognized sleep disorder that affects 0.02%-0.18% of the US and Western European populations. Genetic predisposition is suspected because of narcolepsy's strong association with HLA DQB1*06-02, and genome-wide association studies have identified polymorphisms in T-cell receptor loci. Narcolepsy pathophysiology is linked to loss of signaling by hypocretin-producing neurons; an autoimmune etiology possibly triggered by some environmental agent may precipitate hypocretin neuronal loss...
2017: Nature and Science of Sleep
https://www.readbyqxmd.com/read/28379012/phase-transfer-and-ion-pairing-catalysis-of-pentanidiums-and-bisguanidiniums
#2
Lili Zong, Choon-Hong Tan
Catalysts accelerate biological processes and organic reactions in a controlled and selective fashion. There are continuing efforts in asymmetric catalysis to develop efficient catalysts with broad reaction scope and industrial practicability. Among the various modes of asymmetric catalysis, phase-transfer catalysis has attracted intense interest due to its facile scale up and low catalyst loading. Chiral quaternary ammonium and phosphonium salts are well-studied classes of chiral phase-transfer catalysts, and they are typically composed of sp(3)-hybridized quaternary onium salts...
April 5, 2017: Accounts of Chemical Research
https://www.readbyqxmd.com/read/28364461/double-blind-placebo-controlled-crossover-study-of-armodafinil-treatment-of-daytime-sleepiness-associated-with-treated-nocturia
#3
Andrew D Krystal, Xavier A Preud'homme
Study Objectives: Nocturia, voids which disturb sleep, is the most common cause of awakenings and is associated with daytime sleepiness. Because the standard treatments for the most common causes of nocturia are relatively ineffective, many treated patients with nocturia are left with residual sleepiness. We carried out this pilot study to evaluate the potential of armodafinil to be an effective means of addressing the sleepiness that persists in many nocturia patients, despite their receiving standard therapy...
January 1, 2017: Sleep
https://www.readbyqxmd.com/read/28256707/dopaminergic-agents-in-the-treatment-of-bipolar-depression-a-systematic-review-and-meta-analysis
#4
A G Szmulewicz, F Angriman, C Samamé, A Ferraris, D Vigo, S A Strejilevich
OBJECTIVE: To systematically examine the effects of dopaminergic agents (modafinil, armodafinil, pramipexole, methylphenidate, and amphetamines) on bipolar depression outcomes. METHODS: Meta-analysis of randomized controlled trials was performed to assess the efficacy and safety of treatment with dopaminergic agents in bipolar depression. In a secondary analysis, findings from both randomized controlled trials and high-quality observational studies were pooled by means of meta-analytic procedures to explore dopaminergic treatment-related new mania...
March 3, 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28144880/use-of-stimulants-in-bipolar-disorder
#5
REVIEW
Giulio Perugi, Giulia Vannucchi, Fulvio Bedani, Ettore Favaretto
Several international guidelines indicate stimulants, including methylphenidate (MPH), amphetamines and derivatives, modafinil, and armodafinil among the second-third-line choices for bipolar depression. Efficacy of stimulants has been also reported for the management of residual depressive symptoms such as fatigue and sleepiness and for the management of affective, cognitive, and behavioral symptoms in children and adult bipolar patients with comorbid ADHD. Few case reports show positive results with MPH in the treatment of resistant mania...
January 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/28128982/social-support-insomnia-and-adherence-to-cognitive-behavioral-therapy-for-insomnia-after-cancer-treatment
#6
Charles Kamen, Sheila N Garland, Charles E Heckler, Anita R Peoples, Ian R Kleckner, Calvin L Cole, Michael L Perlis, Gary R Morrow, Karen M Mustian, Joseph A Roscoe
OBJECTIVE/BACKGROUND: While cognitive-behavioral therapy for insomnia (CBT-I) has been shown to be efficacious in treating cancer survivors' insomnia, 30-60% of individuals have difficulty adhering to intervention components. Psychosocial predictors of adherence and response to CBT-I, such as social support, have not been examined in intervention studies for cancer survivors. PARTICIPANTS: Data from a randomized placebo-controlled 2 x 2 trial of CBT-I and armodafinil (a wakefulness promoting agent) were used to assess adherence...
January 27, 2017: Behavioral Sleep Medicine
https://www.readbyqxmd.com/read/28114089/-non-conventional-pharmacological-agents-for-the-treatment-of-bipolar-disorder-%C3%AE-systematic-review-of-the-evidence
#7
K N Fountoulakis, D Balaris, V Nikolaou, J Νimatoudis
Bipolar disorder (BD) has a complex and variable clinical picture which is characterized by many different phacets and phases and as a result its therapeutical options are also complex and often unsatisfactory. Typically the so-called "mood stabilizers" are used in the treatment of BD and in this class lithium and specific antiepileptics are included. The present study aimed to systematically review the literature concerning the presence of randomized double blind clinical trials of 'non conventional' pharmaceutical treatment options...
October 2016: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/28105576/effects-of-cognitive-behavioral-therapy-for-insomnia-and-armodafinil-on-quality-of-life-in-cancer-survivors-a-randomized-placebo-controlled-trial
#8
Anita R Peoples, Sheila N Garland, Michael L Perlis, Josée Savard, Charles E Heckler, Charles S Kamen, Julie L Ryan, Karen M Mustian, Michelle C Janelsins, Luke J Peppone, Gary R Morrow, Joseph A Roscoe
PURPOSE: Cancer-related insomnia is associated with diminished quality of life (QOL), suggesting that improvement in insomnia may improve QOL in cancer survivors. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve insomnia, but less is known regarding its effect on QOL and whether improvement in insomnia corresponds to improved QOL. The present analysis examines the effects of CBT-I, with and without armodafinil, on QOL both directly and indirectly through improvements of insomnia...
January 19, 2017: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/27869124/bisguanidinium-dinuclear-oxodiperoxomolybdosulfate-ion-pair-catalyzed-enantioselective-sulfoxidation
#9
Lili Zong, Chao Wang, Adhitya Mangala Putra Moeljadi, Xinyi Ye, Rakesh Ganguly, Yongxin Li, Hajime Hirao, Choon-Hong Tan
Catalytic use of peroxomolybdate for asymmetric transformations has attracted increasing attention due to its catalytic properties and application in catalysis. Herein, we report chiral bisguanidinium dinuclear oxodiperoxomolybdosulfate [BG](2+)[(μ-SO4)Mo2O2(μ-O2)2(O2)2](2-) ion pair, as a catalyst for enantioselective sulfoxidation using aqueous H2O2 as the terminal oxidant. The ion pair catalyst is isolatable, stable and useful for the oxidation of a range of dialkyl sulfides. The practical utility was illustrated using a gram-scale synthesis of armodafinil, a commercial drug, with the catalyst generated in situ from 0...
November 21, 2016: Nature Communications
https://www.readbyqxmd.com/read/27634806/double-blind-placebo-controlled-cross-over-study-of-armodafinil-treatment-of-daytime-sleepiness-associated-with-treated-nocturia
#10
Andrew D Krystal, Xavier A Preud'homme
STUDY OBJECTIVES: Nocturia, voids which disturb sleep, is the most common cause of awakenings and is associated with daytime sleepiness. Because the standard treatments for the most common causes of nocturia are relatively ineffective, many treated patients with nocturia are left with residual sleepiness. We carried out this pilot study to evaluate the potential of Armodafinil to be an effective means of addressing the sleepiness that persists in many nocturia patients despite their receiving standard therapy...
September 9, 2016: Sleep
https://www.readbyqxmd.com/read/27549768/management-of-narcolepsy
#11
REVIEW
Lucie Barateau, Régis Lopez, Yves Dauvilliers
Narcolepsy type 1 (NT1) and type 2 (NT2) are two rare neurological diseases, classified as central disorders of hypersomnolence. The pathophysiology of NT1 is well known; it is caused by the selective destruction of hypocretin (Hcrt) neurons, by a highly suspected autoimmune process. On the contrary, little is known about NT2 etiology, sharing with NT1 somnolence and signs of dysregulation of rapid eye movement (REM) sleep, but not cataplexy. Management strategies are rather codified, at least in adults, with a lifelong treatment required in NT1, whereas no pharmacological study focused only on NT2 patients, with sometimes spontaneous improvement or disappearance of their symptoms...
October 2016: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/27545285/the-unique-psychostimulant-profile-of-%C3%A2-modafinil-investigation-of-behavioral-and-neurochemical-effects-in-mice
#12
Maddalena Mereu, Lauren E Chun, Thomas E Prisinzano, Amy H Newman, Jonathan L Katz, Gianluigi Tanda
Blockade of dopamine (DA) reuptake via the dopamine transporter (DAT) is a primary mechanism identified as underlying the therapeutic actions of (±)-modafinil (modafinil) and its R-enantiomer, armodafinil. Herein, we explored the neurochemical and behavioral actions of modafinil to better characterize its psychostimulant profile. Swiss-Webster mice were implanted with microdialysis probes in the nucleus accumbens shell (NAS) or core (NAC) to evaluate changes in DA levels related to acute reinforcing actions of drugs of abuse...
January 2017: European Journal of Neuroscience
https://www.readbyqxmd.com/read/27542881/residual-daytime-sleepiness-in-obstructive-sleep-apnea-after-continuous-positive-airway-pressure-optimization-causes-and-management
#13
REVIEW
Julia L Chapman, Yasmina Serinel, Nathaniel S Marshall, Ronald R Grunstein
Excessive daytime sleepiness (EDS) is common in obstructive sleep apnea (OSA), but it is also common in the general population. When sleepiness remains after continuous positive airway pressure (CPAP) treatment of OSA, comorbid conditions or permanent brain injury before CPAP therapy may be the cause of the residual sleepiness. There is currently no broad approach to treating residual EDS in patients with OSA. Individual assessment must be made of comorbid conditions and medications, and of lifestyle factors that may be contributing to the sleepiness...
September 2016: Sleep Medicine Clinics
https://www.readbyqxmd.com/read/27507833/managing-fatigue-in-sarcoidosis-a-systematic-review-of-the-evidence
#14
Chris Atkins, Andrew M Wilson
Fatigue is a common manifestation of sarcoidosis, often persisting without evidence of disease activity. First-line therapies for sarcoidosis have limited effect on fatigue. This review aimed to assess the treatment options targeting sarcoidosis-associated fatigue. Medline and Web of Science were searched in November 2015; the bibliographies of these papers, and relevant review papers, were also searched. Studies were included if they reported on the efficacy of interventions (both pharmacological and non-pharmacological) on fatigue scores in sarcoidosis patients...
August 9, 2016: Chronic Respiratory Disease
https://www.readbyqxmd.com/read/27436172/population-pharmacokinetic-modeling-of-armodafinil-and-its-major-metabolites
#15
Susan Willavize, Jill Fiedler-Kelly, Elizabeth Ludwig, Lingling Guan
Population pharmacokinetic models for armodafinil and its major metabolites, R-modafinil acid and modafinil sulfone, were developed, and selected covariates were investigated. Data from 583 healthy subjects and patients with bipolar I disorder in 11 phase 1-3 studies (8027 concentrations) of armodafinil, given as single or multiple once-daily doses (50- to 400-mg tablet or capsule), were pooled. A previously developed 1-compartment model with first-order absorption without covariate effects was initially applied to pooled phase 1 and 2 data...
February 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27318221/effects-of-armodafinil-and-cognitive-behavior-therapy-for-insomnia-on-sleep-continuity-and-daytime-sleepiness-in-cancer-survivors
#16
Sheila N Garland, Joseph A Roscoe, Charles E Heckler, Holly Barilla, Philip Gehrman, James C Findley, Anita R Peoples, Gary R Morrow, Charles Kamen, Michael L Perlis
STUDY OBJECTIVES: This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors. Whether or not armodafinil alone, and/or when combined with CBT-I, affected adherence with CBT-I was evaluated. DESIGN: This study is a randomized, placebo-controlled, clinical trial...
April 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27155860/treatment-options-for-narcolepsy
#17
REVIEW
Lucie Barateau, Régis Lopez, Yves Dauvilliers
Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy absent. Despite major advances in our understanding of narcolepsy mechanisms, its current management is only symptomatic. Treatment options may vary from a single drug that targets several symptoms, or multiple medications that each treats a specific symptom...
May 2016: CNS Drugs
https://www.readbyqxmd.com/read/26970266/long-term-safety-and-efficacy-of-armodafinil-in-bipolar-depression-a-6-month-open-label-extension-study
#18
RANDOMIZED CONTROLLED TRIAL
Terence A Ketter, Jess Amchin, Mark A Frye, Nicholas Gross
BACKGROUND: Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable efficacy results. METHODS: Completers of three 8-week, double-blind, placebo-controlled adjunctive armodafinil studies (150-200 mg/day added to ongoing stable maintenance doses of 1 or 2 protocol-defined mood stabilizers) in bipolar I depression could enter this 6-month, open-label extension study...
June 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/26923035/effects-of-modafinil-and-armodafinil-in-patients-with-obstructive-sleep-apnea-a-meta-analysis-of-randomized-controlled-trials
#19
Yi-Chun Kuan, Dean Wu, Kuang-Wei Huang, Nai-Fang Chi, Chaur-Jong Hu, Chen-Chih Chung, Ka-Wai Tam, Yao-Hsien Huang
PURPOSE: Obstructive sleep apnea (OSA) is associated with nocturnal hypoxemia, excessive daytime sleepiness (EDS), and sympathetic hyperactivation. Continuous positive airway pressure is the first-line treatment for OSA. However, some patients may have residual EDS. Modafinil and its R-enantiomer, armodafinil, are wakefulness-promoting agents known to be effective in alleviating sleepiness. METHODS: We performed a systematic review and meta-analysis of data from published randomized controlled trials (RCTs) that evaluated the efficacy of modafinil and armodafinil in treating EDS in patients with OSA...
2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/26908128/a-critical-review-of-properties-of-modafinil-and-analytical-bioanalytical-methods-for-its-determination
#20
REVIEW
B Ramachandra
Modafinil is a synthetic molecule used for the treatment of narcolepsy. Narcolepsy is a neurological disorder, due to which people experience frequent excessive daytime sleepiness (EDS). Nevertheless, there are some concerns about modafnil quality control. The modafinil enantiomers are both biologically active. However, it has been reported that the pharmacological properties of the both enantiomers are different and that the S-enantiomer is eliminated three times faster than the R-enantiomer. Therefore, most of the pharmaceutical companies have shifted to produce armodafinil (R-enantiomer) instead of the racemate...
November 2016: Critical Reviews in Analytical Chemistry
keyword
keyword
5555
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"